These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 1810439

  • 1. Effective immunotherapy with local low doses of interleukin-2.
    Den Otter W, Maas RA, Koten JW, Dullens HF, Bernsen M, Klein WR, Rutten VP, Steerenberg PA, Balemans L, Ruitenberg EJ.
    In Vivo; 1991; 5(6):561-5. PubMed ID: 1810439
    [Abstract] [Full Text] [Related]

  • 2. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E, Lafreniere R, Mulé JJ, Schwarz SL, Rosenberg SA.
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [Abstract] [Full Text] [Related]

  • 3. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2.
    Maas RA, Dullens HF, De Jong WH, Den Otter W.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):7037-40. PubMed ID: 2582444
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct 15; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mechanisms of tumor regression induced by low doses of interleukin-2.
    Maas RA, Dullens HF, Den Otter W.
    In Vivo; 1991 Oct 15; 5(6):637-41. PubMed ID: 1810449
    [Abstract] [Full Text] [Related]

  • 8. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
    Maas RA, Roest PA, Becker MJ, Weimar IS, Dullens HF, Den Otter W.
    Immunobiology; 1992 Nov 15; 186(3-4):214-29. PubMed ID: 1490728
    [Abstract] [Full Text] [Related]

  • 9. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R, Rosenberg SA.
    Cancer Res; 1985 Aug 15; 45(8):3735-41. PubMed ID: 3893689
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE, Rosenberg SA.
    Cancer Res; 1986 Jun 15; 46(6):2784-92. PubMed ID: 3486038
    [Abstract] [Full Text] [Related]

  • 11. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R, Rosenberg SA.
    J Immunol; 1985 Dec 15; 135(6):4273-80. PubMed ID: 3877766
    [Abstract] [Full Text] [Related]

  • 12. Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens.
    Baral E, Nagy E, Kangas L, Berczi I.
    Anticancer Res; 1997 Dec 15; 17(5A):3653-8. PubMed ID: 9413218
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administration.
    Everse LA, Bernsen MR, Dullens HF, Den Otter W.
    J Exp Ther Oncol; 1996 Jul 15; 1(4):231-6. PubMed ID: 9414409
    [Abstract] [Full Text] [Related]

  • 17. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ.
    Cancer Res; 1988 Sep 01; 48(17):5007-10. PubMed ID: 3261630
    [Abstract] [Full Text] [Related]

  • 18. Locoregional administration of etoposide, but not of interleukin 2, facilitates active specific immunization in guinea pigs with advanced carcinoma.
    Claessen AM, Bloemena E, Bril H, Meijer CJ, Scheper RJ.
    Cancer Res; 1992 May 01; 52(9):2440-6. PubMed ID: 1568214
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW.
    Cancer Res; 2001 Mar 01; 61(5):1948-56. PubMed ID: 11280751
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.